582 related articles for article (PubMed ID: 9755726)
1. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
Aboagye EO; Kelson AB; Tracy M; Workman P
Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.
Aboagye EO; Maxwell RJ; Kelson AB; Tracy M; Lewis AD; Graham MA; Horsman MR; Griffiths JR; Workman P
Cancer Res; 1997 Aug; 57(15):3314-8. PubMed ID: 9242466
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554.
Aboagye EO; Lewis AD; Graham MA; Tracy M; Kelson AB; Ryan KJ; Workman P
Anticancer Drug Des; 1996 Apr; 11(3):231-42. PubMed ID: 8663910
[TBL] [Abstract][Full Text] [Related]
4. Novel fluorinated hypoxia-targeted compounds as Non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS).
Papadopoulou MV; Ji M; Bloomer WD
Anticancer Res; 2006; 26(5A):3253-8. PubMed ID: 17094437
[TBL] [Abstract][Full Text] [Related]
5. Novel non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Studies in the SCCVII/C3H murine model.
Papadopoulou MV; Pouremad R; Bloomer WD; Wyrwicz A
Anticancer Res; 2006; 26(5A):3259-63. PubMed ID: 17094438
[TBL] [Abstract][Full Text] [Related]
6. In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors.
Procissi D; Claus F; Burgman P; Koziorowski J; Chapman JD; Thakur SB; Matei C; Ling CC; Koutcher JA
Clin Cancer Res; 2007 Jun; 13(12):3738-47. PubMed ID: 17575240
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-trifluoromethylquinoline hydrochloride (NLTQ-1), a new bioreductive agent as a hypoxia marker by 19F-magnetic resonance spectroscopy (19F-MRS).
Papadopoulou MV; Pouremad R; Rao MK; Ji M; Bloomer WD
In Vivo; 2001; 15(5):365-71. PubMed ID: 11695231
[TBL] [Abstract][Full Text] [Related]
8. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy.
Seddon BM; Maxwell RJ; Honess DJ; Grimshaw R; Raynaud F; Tozer GM; Workman P
Clin Cancer Res; 2002 Jul; 8(7):2323-35. PubMed ID: 12114437
[TBL] [Abstract][Full Text] [Related]
9. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ].
Busch TM; Hahn SM; Evans SM; Koch CJ
Cancer Res; 2000 May; 60(10):2636-42. PubMed ID: 10825135
[TBL] [Abstract][Full Text] [Related]
10. The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554.
Aboagye EO; Maxwell RJ; Horsman MR; Lewis AD; Workman P; Tracy M; Griffiths JR
Br J Cancer; 1998; 77(1):65-70. PubMed ID: 9459147
[TBL] [Abstract][Full Text] [Related]
11. Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554).
Aboagye EO; Lewis AD; Tracy M; Workman P
Biochem Pharmacol; 1997 Dec; 54(11):1217-24. PubMed ID: 9416972
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance spectroscopy for measuring the biodistribution and in situ in vivo pharmacokinetics of fluorinated compounds: validation using an investigation of liver and heart disposition of tecastemizole.
Schneider E; Bolo NR; Frederick B; Wilkinson S; Hirashima F; Nassar L; Lyoo IK; Koch P; Jones S; Hwang J; Sung Y; Villafuerte RA; Maier G; Hsu R; Hashoian R; Renshaw PF
J Clin Pharm Ther; 2006 Jun; 31(3):261-73. PubMed ID: 16789992
[TBL] [Abstract][Full Text] [Related]
13. The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis.
Aboagye EO; Lewis AD; Johnson A; Workman P; Tracy M; Huxham IM
Br J Cancer; 1995 Aug; 72(2):312-8. PubMed ID: 7640211
[TBL] [Abstract][Full Text] [Related]
14. PET and PET/CT studies of tumor tissue oxygenation.
Krause BJ; Beck R; Souvatzoglou M; Piert M
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):28-43. PubMed ID: 16557202
[TBL] [Abstract][Full Text] [Related]
15. Relation between pO2, 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy.
Dewhirst MW; Poulson JM; Yu D; Sanders L; Lora-Michiels M; Vujaskovic Z; Jones EL; Samulski TV; Powers BE; Brizel DM; Prosnitz LR; Charles HC
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):480-91. PubMed ID: 15667971
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs.
Siim BG; Atwell GJ; Anderson RF; Wardman P; Pullen SM; Wilson WR; Denny WA
J Med Chem; 1997 Apr; 40(9):1381-90. PubMed ID: 9135035
[TBL] [Abstract][Full Text] [Related]
17. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts.
Lord EM; Harwell L; Koch CJ
Cancer Res; 1993 Dec; 53(23):5721-6. PubMed ID: 8242628
[TBL] [Abstract][Full Text] [Related]
18. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
19. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland.
Stone HB; Brown JM; Phillips TL; Sutherland RM
Radiat Res; 1993 Dec; 136(3):422-34. PubMed ID: 8278585
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy.
Seddon BM; Payne GS; Simmons L; Ruddle R; Grimshaw R; Tan S; Turner A; Raynaud F; Halbert G; Leach MO; Judson I; Workman P
Clin Cancer Res; 2003 Nov; 9(14):5101-12. PubMed ID: 14613987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
